TY - JOUR
T1 - REDD1 (regulated in development and DNA damage response 1) expression in skeletal muscle as a surrogate biomarker of the efficiency of glucocorticoid receptor blockade
AU - Kumari, Rashmi
AU - Willing, Lisa B.
AU - Jefferson, Leonard S.
AU - Simpson, Ian A.
AU - Kimball, Scot R.
N1 - Funding Information:
The authors wish to thank Sharon L. Rannels for help with Western blot analysis. The studies described herein were supported by National Institutes of Health Grants DK75130 (to I.A.S.) and DK-15658 (to L.S.J.).
PY - 2011/9/9
Y1 - 2011/9/9
N2 - Glucocorticoids are potent regulators of cell metabolism, and in part act through a receptor-based mechanism to alter the transcription of target genes. A plethora of studies have utilized the glucocorticoid receptor antagonist, RU-486, both in vivo and in vitro, to reverse or prevent hormone-induced alterations in gene transcription. However, although RU-486 potently blocks many of the functions of the receptor, it does not lower plasma concentrations of the hormone, and a biomarker for the effectiveness of RU-486 in blocking receptor activation is lacking. In the present study, we demonstrate glucocorticoid-induced changes in expression of a protein referred to as regulated in development and DNA damage response (REDD1) in a variety of mouse models of hypercortisolemia including stroke, type 2 diabetes, and stress induced by confinement. Notably REDD1 expression in skeletal muscle positively correlated with changes in corticosterone concentrations in all conditions. RU-486 had no effect on corticosterone concentrations, but strongly attenuated the stroke-, diabetes-, and stress-induced changes in REDD1 expression. Overall, the results of the present study suggest that changes in REDD1 expression in skeletal muscle represent an excellent surrogate biomarker for the efficacy of RU-486 treatment in repressing glucocorticoid action.
AB - Glucocorticoids are potent regulators of cell metabolism, and in part act through a receptor-based mechanism to alter the transcription of target genes. A plethora of studies have utilized the glucocorticoid receptor antagonist, RU-486, both in vivo and in vitro, to reverse or prevent hormone-induced alterations in gene transcription. However, although RU-486 potently blocks many of the functions of the receptor, it does not lower plasma concentrations of the hormone, and a biomarker for the effectiveness of RU-486 in blocking receptor activation is lacking. In the present study, we demonstrate glucocorticoid-induced changes in expression of a protein referred to as regulated in development and DNA damage response (REDD1) in a variety of mouse models of hypercortisolemia including stroke, type 2 diabetes, and stress induced by confinement. Notably REDD1 expression in skeletal muscle positively correlated with changes in corticosterone concentrations in all conditions. RU-486 had no effect on corticosterone concentrations, but strongly attenuated the stroke-, diabetes-, and stress-induced changes in REDD1 expression. Overall, the results of the present study suggest that changes in REDD1 expression in skeletal muscle represent an excellent surrogate biomarker for the efficacy of RU-486 treatment in repressing glucocorticoid action.
UR - http://www.scopus.com/inward/record.url?scp=80052635943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052635943&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2011.08.017
DO - 10.1016/j.bbrc.2011.08.017
M3 - Article
C2 - 21856283
AN - SCOPUS:80052635943
SN - 0006-291X
VL - 412
SP - 644
EP - 647
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 4
ER -
